Skip to Content

Mayo Clinic Laboratory and Pathology Research Roundup: April 18

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.


Featured Study of the Week

Assessing the Value of LMO2 as a Biomarker for T-Lymphoblastic Leukemia/Lymphoma

t-cell-960x540T-lymphoblastic leukemia/lymphoma (also known as T-cell acute lymphoblastic leukemia or “T‑ALL”) is an aggressive cancer caused by an overproduction of immature T cells. Recent research suggests that the protein LMO2 appears to be a biomarker of transformed T‑precursor cells. In a recent study published in the American Journal of Clinical Pathology, Mayo Clinic researchers tested the specificity of LMO2 for distinction between neoplastic and non-neoplastic T-precursor cells in the thymus and bone marrow.


Published to PubMed This Week

Kelley Luedke

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.